Thrombocytopenia after isolated limb or hepatic perfusions with melphalan: The risk of heparin-induced thrombocytopenia

Annals of Surgical Oncology

Volumn 6, Issue 5, 1999, Pages 476-480

  Masucci, Iris P ^a   Calis, Karim A ^a   Bartlett, David L ^b   Alexander, H Richard ^b   Horne III, McDonald K ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Heparin; Thrombocytopenia

Indexed keywords

DRUG ANTIBODY; HEPARIN; MELPHALAN;

ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; HEPARINIZATION; HUMAN; HUMAN TISSUE; LIMB PERFUSION; LIVER PERFUSION; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; ANTIBODIES; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARIN; HUMANS; MEDICAL RECORDS; MELPHALAN; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 0032771003     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0476-7     Document Type: Article

References (21)

1. Krementz ET, Ryan RF, Carter RD, Sutherland CM, Reed RJ. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Milton GW, eds. Cutaneous Melanoma. Philadelphia: JB Lippincott, 1985:171-95.
2. Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
3. Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 1996;12:416.
4. McBride CM, Sugarbaker EV, Hickey RC. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 1975;182:316-24.
5. Collins R, Scrimgeour A, Yusuf S, Peta R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988;318: 1162-73.
6. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993;305:208-15.
7. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100:535-40.
8. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
9. Alexander HR, Bartlett DL, Libutti SK. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J 1998;4:2-11.
10. Horne MK, Alkins BR. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med 1996;127: 435-42.
11. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
12. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:648-52.
13. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis, In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds, Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia: JB Lippincott, 1994:1275-96.
14. Khuri SF, Wolfe JA, Josa M, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992;104:94-107.
15. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995;13: 264-73.
16. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 1996;128:376-83.
17. Bauer TL, Arepally G, Konkel BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-6.
18. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac A-M, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-5.
19. Suh J-S, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201.
20. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554-60.
21. Greinacher A, Volpel H, Potzsch B. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Blood 1996;88(Suppl 1):281a.